E7 proteins from oncogenic human papillomavirus types transactivate p73 : role in cervical intraepithelial neoplasia
Copyright 2002 The Cancer Research Campaign.
In common with other E2F1 responsive genes such as p14(ARF) and B-myb, the promoter of p73 is shown to be positively regulated in cell lines and primary human keratinocytes by E7 proteins from oncogenic human papillomavirus (HPV) types 16, 18, 31 and 33, but not HPV 6. Mutational analysis revealed that transactivation of the p73 promoter by HPV 16E7 requires association with pRb. Expression of p73 in normal cervical epithelium is confined to the basal and supra-basal layers. In contrast, expression in neoplastic lesions is detected throughout the epithelium and increases with grade of neoplasia, being maximal in squamous cell cancers (SCC). Deregulation of expression of the N-terminal splice variant p73Delta2 was observed in a significant proportion of cancers, but not in normal epithelium. The frequent over-expression of p73Delta2, which has recognized transdominant properties, in malignant and pre-malignant lesions suggests a role in the oncogenic process in cervical epithelium.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2002 |
|---|---|
| Erschienen: |
2002 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
British journal of cancer - 86(2002), 2 vom: 21. Jan., Seite 263-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brooks, L A [VerfasserIn] |
|---|
| Themen: |
DNA-Binding Proteins |
|---|
| Anmerkungen: |
Date Completed 12.03.2002 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM117555797 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM117555797 | ||
| 003 | DE-627 | ||
| 005 | 20231222180800.0 | ||
| 007 | tu | ||
| 008 | 231222s2002 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0392.xml |
| 035 | |a (DE-627)NLM117555797 | ||
| 035 | |a (NLM)11870517 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brooks, L A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a E7 proteins from oncogenic human papillomavirus types transactivate p73 |b role in cervical intraepithelial neoplasia |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2002 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2002 The Cancer Research Campaign | ||
| 520 | |a In common with other E2F1 responsive genes such as p14(ARF) and B-myb, the promoter of p73 is shown to be positively regulated in cell lines and primary human keratinocytes by E7 proteins from oncogenic human papillomavirus (HPV) types 16, 18, 31 and 33, but not HPV 6. Mutational analysis revealed that transactivation of the p73 promoter by HPV 16E7 requires association with pRb. Expression of p73 in normal cervical epithelium is confined to the basal and supra-basal layers. In contrast, expression in neoplastic lesions is detected throughout the epithelium and increases with grade of neoplasia, being maximal in squamous cell cancers (SCC). Deregulation of expression of the N-terminal splice variant p73Delta2 was observed in a significant proportion of cancers, but not in normal epithelium. The frequent over-expression of p73Delta2, which has recognized transdominant properties, in malignant and pre-malignant lesions suggests a role in the oncogenic process in cervical epithelium | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a E6 protein, Human papillomavirus type 6 |2 NLM | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Viral |2 NLM | |
| 650 | 7 | |a TP73 protein, human |2 NLM | |
| 650 | 7 | |a Tumor Protein p73 |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 700 | 1 | |a Sullivan, A |e verfasserin |4 aut | |
| 700 | 1 | |a O'Nions, J |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, A |e verfasserin |4 aut | |
| 700 | 1 | |a Dunne, B |e verfasserin |4 aut | |
| 700 | 1 | |a Tidy, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, D J |e verfasserin |4 aut | |
| 700 | 1 | |a Osin, P |e verfasserin |4 aut | |
| 700 | 1 | |a Vousden, K H |e verfasserin |4 aut | |
| 700 | 1 | |a Gusterson, B |e verfasserin |4 aut | |
| 700 | 1 | |a Farrell, P J |e verfasserin |4 aut | |
| 700 | 1 | |a Storey, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gasco, M |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, T |e verfasserin |4 aut | |
| 700 | 1 | |a Crook, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 86(2002), 2 vom: 21. Jan., Seite 263-8 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2002 |g number:2 |g day:21 |g month:01 |g pages:263-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2002 |e 2 |b 21 |c 01 |h 263-8 | ||